Gb Sciences is a drug development and biopharmaceutical research company that began developing its proprietary digital research and analytics platform even before the pandemic prompted a digital change.

According to a Deloitte report, biopharma lags behind other industries in digital transformation. Eighty percent of study respondents (including 150 executives from prominent biopharma businesses) say their organization must be more proactive and implement digital technology more quickly to compete in the market. The Phytomedical Analytics for Research Optimization at Scale platform, or PhAROSTM for short, developed by Gb Sciences, successfully leverages data analytics and machine learning to speed the drug development research procedures in order to bring new, plant-inspired products to market faster.

PhAROSTM may be the finest toolkit for discovering the “Future of Medicine”: a blend of Artificial Intelligence (AI) technology, traditional plant-based medicine, and science that enables scientists to find and evaluate tailored ingredient mixes for the treatment of complicated disorders. Our researchers can use our PhAROSTM platform to uncover suitable complicated, multi-ingredient medicines for treating complex human disorders.

The CSO and President of Gb Sciences, Dr. Andrea Small-Howard, stated, “The use of AI and computer modeling for biomedical research presents an untapped opportunity to discover plant-inspired medicines reflecting the vast knowledge of traditional medicines, but simplified. Gb Science uses machine learning to identify potentially effective combinations of drugs amongst the known traditional medicine systems in a complex view of human diseases. The PhAROS™ platform yields numerous potentially effective, plant-inspired combination drugs to help millions worldwide and also pre-screens these drug candidates for potentially unwanted side effects.”

Gb Sciences developed unique and patentable subsets of phytochemicals with medicinal promise using sequential in silico, in vitro, and in vivo screens, which were verified in cell and animal models. Using digital technology, Gb discovered its patent-pending formulations for Parkinson’s disease, depression, chronic pain, COVID-cytokine release syndrome, and heart disease. As Gb uses PhAROSTM to locate more commonly available biosimilars of plants worldwide, digital technologies not only improve medical research and lower production costs but also provide an edge in supply chain stability.

Featured Image: Megapixl @Prometeus